ClinicalTrials.gov
ClinicalTrials.gov Menu

RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02991807
Recruitment Status : Recruiting
First Posted : December 14, 2016
Last Update Posted : November 16, 2018
Sponsor:
Collaborators:
National Institutes of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Office of Rare Diseases (ORD)
National Center for Advancing Translational Science (NCATS)
Novartis Pharmaceuticals
PTEN Research
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Information provided by (Responsible Party):
Mustafa Sahin, Boston Children’s Hospital

Brief Summary:
Phosphatase and TENsin homolog (PTEN) gene germline mutations are associated with a spectrum of clinical manifestations characterized by neurocognitive deficits, intellectual disability, autism symptomatology, skin lesions, macrocephaly, hamartomatous overgrowth of tissues, and an increased risk of cancers. Investigators are conducting research to evaluate the potential safety and efficacy of RAD001 (everolimus) in this patient population, and the potential neurocognitive benefits from treatment with RAD001 or placebo for a six month period. The investigators hope this trial will lead to a better understanding of PTEN and to new forms of treatment that may benefit children and adults with PTEN in the future.

Condition or disease Intervention/treatment Phase
PTEN Gene Mutation PTEN Hamartoma Tumor Syndrome Drug: RAD001 Drug: Placebo Phase 1 Phase 2

Detailed Description:

This is a signal seeking Phase I/II 6-month, randomized, double-blind placebo-controlled trial of everolimus in individuals, ages 5 to 45 years with a PTEN mutation, with safety and neurocognition as the primary endpoints.

Participant's or a legal guardian will need to sign an informed consent prior to enrollment in the study. To determine eligibility participants will undergo a series of screening tests and safety measures. If determined to be eligible for the blinded phase of the study, participants will be randomly assigned to take either the study drug or a placebo (pill with no medicine).

The blinded phase of the study involves about eight visits, five of which will occur at the study site, and three of which will be conducted over the phone. These visits will take place over a six month period. Study visits will vary in length. Baseline, three month and six month visits may last up to 8 hours, if optional measures are done, while all other visits will be less than 2 hours. The study visits include blood draws, general health exams, and neuropsychological assessments. The study will also include optional eye-tracking, EEG and auditory evoked potential (AEP) measures, and the collection of microbiome/mycobiome and biomarker blood sample. There is no fee to participate in this study. The study drug will be provided at no charge during the study.

After the 6 month treatment phase, individuals who were randomly assigned to take placebo will be offered inclusion in a 6 month open label phase where the study drug will be provided at no charge. The open label phase assessments will be similar to those done in the blinded phase, but patients/families will only need to return to the study site three times during this phase.

Participants will receive a developmental assessments report after completing the study. After all study data has been analyzed, patients and families will also be informed of the overall results. Treatment on this study may or may not improve an individual's learning skills (neurocognition) or behavior. We hope that future patients and families will benefit from what is learned by this study.

Specific Aims /Objectives Primary objective

-To evaluate the safety of everolimus compared with placebo in patients with PTEN mutations focusing on NCI CTCAE Grade 3 and 4 adverse events, serious adverse events, and Grade 3 and 4 laboratory toxicities.

Secondary objectives

-To evaluate the efficacy of everolimus on neurocognition and behavior in inividuals with PTEN mutations compared to placebo as measured by standardized, direct and indirect neurocognitive tools and behavioral measures.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized Double-Blind Controlled Trial of Everolimus in Individuals With PTEN Mutations (RAD001XUS257T)
Actual Study Start Date : June 12, 2017
Estimated Primary Completion Date : June 2019
Estimated Study Completion Date : June 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: RAD001
RAD001 is formulated as tablets of 5.0 mg or 2.5mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis.
Drug: RAD001

RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis. RAD001 tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.

Patients will be instructed to take 4.5 mg/m2 of RAD001 orally with a glass of water at regular intervals at the same time (delete: each day) in the morning after a light, nonfat breakfast.

Other Names:
  • Everolimus
  • Afinitor

Placebo Comparator: Placebo
Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10.
Drug: Placebo

Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10. Matching placebo tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.

Patients will be instructed to take 4.5 mg/m2 of the matching placebo orally with a glass of water at regular intervals at the same time (delete: each day) in the morning after a light, nonfat breakfast.





Primary Outcome Measures :
  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: Through study completion, an average of 6 months ]
    The primary endpoint will be safety as measured by study drop-out rate due to side effects, comparing everolimus vs. placebo. We will also determine the frequency of adverse events by type and severity.


Secondary Outcome Measures :
  1. Change in Working Memory at 6 Months [ Time Frame: 6 months ]
    Working memory will be evaluated using the Stanford Binet 5 or Mullen Scales of Early Learning at 6 months

  2. Change in Processing Speed at 3 Months [ Time Frame: 3 months ]
    Processing speed will be evaluated using mean reaction time on the Conner's Continuous Performance Test (CPT)-3.

  3. Change in Processing Speed at 6 Months [ Time Frame: 6 months ]
    Processing speed will be evaluated using mean reaction time on the Conner's Continuous Performance Test (CPT)-3.

  4. Change in Fine Motor Skills at 3 Months [ Time Frame: 3 months ]
    Fine motor skills will be evaluated using the Purdue Pegboard sub-tests average of both hands

  5. Change in Fine Motor Skills at 6 Months [ Time Frame: 6 months ]
    Fine motor skills will be evaluated using the Purdue Pegboard sub-tests average of both hands

  6. Change in Attention at 3 Months [ Time Frame: 3 months ]
    Attention will be measured by Conners' Continuous Performance Test - 3 - Discriminability index (d') and Omissions

  7. Change in Attention at 6 Months [ Time Frame: 6 months ]
    Attention will be measured by Conners' Continuous Performance Test - 3 - Discriminability index (d') and Omissions

  8. Change in Impulsivity at 3 Months [ Time Frame: 3 months ]
    Impulsivity will be measured by Conners' Continuous Performance Test-3- Commissions and Bias (B').

  9. Change in Impulsivity at 6 Months [ Time Frame: 6 months ]
    Impulsivity will be measured by Conners' Continuous Performance Test-3- Commissions and Bias (B').

  10. Change in Global Cognitive Ability at 6 Months [ Time Frame: 6 months ]
    Change in global cognitive ability will be measured by Stanford-Binet 5 or Mullen; Full scale, verbal and nonverbal ability (IQ)

  11. Change in Motor Functioning at 3 Months [ Time Frame: 3 months ]
    Motor functioning will be measured by the Purdue Pegboard (Pegs): Dominant and non-dominant hand combined standard scores and Developmental Coordination Disorder Questionnaire (DCDQ): Total score.

  12. Change in Motor Functioning at 6 Months [ Time Frame: 6 months ]
    Motor functioning will be measured by the Purdue Pegboard (Pegs): Dominant and non-dominant hand combined standard scores and Developmental Coordination Disorder Questionnaire (DCDQ): Total score.

  13. Change in Communication Ability at 3 Months [ Time Frame: 3 months ]
    Communication ability will be measured by using standard scores of the Peabody Picture Vocabulary Test (PPVT-4), Expressive Vocabulary Test (EVT-2)

  14. Change in Communication Ability at 6 Months [ Time Frame: 6 months ]
    Communication ability will be measured by using standard scores of the Peabody Picture Vocabulary Test (PPVT-4), Expressive Vocabulary Test (EVT-2)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   5 Years to 45 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male and female outpatients between 5 and 45 years of age (inclusive);
  2. Pathogenic PTEN mutation confirmed by clinical genetic testing;
  3. IQ ≥ 50 (either verbal, nonverbal, or full scale IQ) (IQ necessary to be able to complete the required neurocognitive and developmental assessments)
  4. Performance below the age-adjusted population mean on at least one standardized measure such as attention (CPT-3, mean reaction time), working memory (SB5), or fine motor skills (Purdue Pegboard Test; either dominant hand, non-dominant hand, or both hands);
  5. Adequate bone marrow function as shown by:

    1. platelets ≥ 80,000/mm3
    2. absolute neutrophil count ≥ 1,000/mm3
    3. hemoglobin ≥ 9 g/dL
  6. Adequate liver function as shown by:

    1. Total serum bilirubin < 1.5 x ULN
    2. AST and ALT levels < 2.5 x ULN
    3. INR ≤ 2
  7. Adequate renal function: serum creatinine < 1.5 x ULN,
  8. Signed informed consent obtained prior to any screening procedures;
  9. Individuals on psychotropic and anti-epileptic medications should maintain a stable dose for at least 2 months prior to the screening visit;
  10. Negative serum pregnancy test for females at screening and no plans to become pregnant or conceive a child while participating in the study. The effects of mTOR inhibitors on the developing fetus at the doses used in this study are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of the study. Estrogen-containing oral contraceptives are not recommended in women enrolled in this study. Abstinence or two effective non-estrogen or barrier methods of contraception (such as condoms + spermicidal foam) must be used;
  11. No anticipated changes in the frequency and intensity of existing interventions such as behavioral and developmental treatments, in home services, and speech therapy;
  12. No planned changes in school placement;
  13. For individuals under 18 or who are otherwise incapable, there must be an available caregiver who can reliably bring subject to clinic visits and provide trustworthy data
  14. Able to communicate fluently in English

Double-Blind Exclusion Criteria

  1. Patients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of the start of Everolimus (including chemotherapy, radiation therapy, antibody based therapy, etc.);
  2. Known intolerance or hypersensitivity to Everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus);
  3. Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral Everolimus;
  4. Uncontrolled diabetes mellitus as defined by HbA1c >8% despite adequate therapy. Patients with a known history of impaired fasting glucose or diabetes mellitus (DM) may be included, however blood glucose and antidiabetic treatment must be monitored closely throughout the trial and adjusted as necessary;
  5. Patient with uncontrolled hyperlipidemia: fasting serum cholesterol > 300 mg/dL OR >7.75 mmol/L AND fasting triglycerides > 2.5 x ULN.
  6. Patients who have any severe and/or uncontrolled medical or psychiatric conditions (see section 4.6 for additional details)
  7. Chronic treatment with corticosteroids or other immunosuppressive agents. Topical or inhaled corticosteroids are allowed;
  8. Known history of or seropositivity for Hepatitis B, Hepatitis C, or HIV;
  9. Patients who have received live attenuated vaccines within 1 week of start of Everolimus and during the study. Patient should also avoid close contact with others who have received live attenuated vaccines. Examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, BCG, yellow fever, varicella and TY21a typhoid vaccines;
  10. Patients who have a history of another primary malignancy, with the exceptions of:

    1. non-melanoma skin cancer,
    2. and carcinoma in situ of the cervix, uteri, or breast from which the patient has been disease free for ≥3 years;
  11. Planned changes to concomitant medications;
  12. Prior or concomitant therapy with known or possible anti-mTOR activity, including rapamycin (sirolimus);
  13. Concomitant therapy with strong inhibitor (e.g., cyclosporine and ketoconazole) or inducer of CYP3A;
  14. Active infection at time of enrollment;
  15. Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable or will not be able to complete the entire study;
  16. Patients who are currently part of or have participated in any clinical investigation with an investigational drug within 1 month prior to dosing;
  17. Pregnant or nursing (lactating) women;
  18. Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, must use highly effective methods of contraception during the study and 8 weeks after. Highly effective contraception methods include:

    a. A combination of any two of the following:

    i. Use of oral, injected or implanted hormonal non-estrogen containing methods of contraception or;

    ii. Placement of an intrauterine device (IUD) or intrauterine system (IUS);

    iii. Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal suppository;

    b. Total abstinence or;

    c. Male/female sterilization. Women are considered post-menopausal and not of child-bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks prior to randomization. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child-bearing potential.

  19. Male patients whose sexual partner(s) are WOCBP who are not willing to use adequate contraception, during the study and for 8 weeks after the end of treatment
  20. Major surgery, radiation therapy, or stereotactic radio-surgery within previous 4 weeks at time of screening
  21. Neurosurgery within prior 6 months at time of screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02991807


Contacts
Contact: Amelia Diplock 617-919-1476 Amelia.Diplock@childrens.harvard.edu
Contact: Rajna Filip-Dhima, MS 617-919-7068 Rajna.Filip-Dhima@childrens.harvard.edu

Locations
United States, California
Stanford University Recruiting
Palo Alto, California, United States, 94305
Contact: Jaelyn Edwards    650-736-1235    jedwrds@stanford.edu   
Contact: Stephanie Ghassan    650-736-1235    stephgh@stanford.edu   
Principal Investigator: Antonio Hardan, MD         
United States, Massachusetts
Boston Children's Hospital Recruiting
Boston, Massachusetts, United States, 02115
Contact: Amelia Diplock    617-919-1476    Amelia.Diplock@childrens.harvard.edu   
Contact: Rajna Filip-Dhima, MS    617-919-7068    Rajna.Filip-Dhima@childrens.harvard.edu   
Principal Investigator: Mustafa Sahin, MD, PhD         
United States, Ohio
Cleveland Clinic Recruiting
Cleveland, Ohio, United States, 44104
Contact: Komeisha Rose    216-445-8798    ROSEK2@ccf.org   
Principal Investigator: Rabi Hanna, MD         
Sub-Investigator: Charis Eng, MD,PhD         
Sponsors and Collaborators
Boston Children’s Hospital
National Institutes of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Office of Rare Diseases (ORD)
National Center for Advancing Translational Science (NCATS)
Novartis Pharmaceuticals
PTEN Research
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Investigators
Principal Investigator: Mustafa Sahin, MD, PhD Boston Children’s Hospital

Additional Information:
Responsible Party: Mustafa Sahin, Director, Translational Neuroscience Center/ Professor of Neurology, Harvard Medical School, Boston Children’s Hospital
ClinicalTrials.gov Identifier: NCT02991807     History of Changes
Other Study ID Numbers: IRB-P00020332
1U54NS092090 ( U.S. NIH Grant/Contract )
First Posted: December 14, 2016    Key Record Dates
Last Update Posted: November 16, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Data will be shared with the National Database of Autism Research (NDAR)

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Mustafa Sahin, Boston Children’s Hospital:
PTEN
PTEN Gene Mutation
PTEN Hamartoma Tumor Syndrome
Autism
Intellectual Disability
Neurocognition
Afinitor
Everolimus
RAD001

Additional relevant MeSH terms:
Syndrome
Hamartoma
Neoplasms
Hamartoma Syndrome, Multiple
Disease
Pathologic Processes
Neoplasms, Multiple Primary
Neoplastic Syndromes, Hereditary
Genetic Diseases, Inborn
Everolimus
Sirolimus
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents